Company Profile

Bristol-Myers Squibb Company

345 Park Avenue

New York New York 10154 U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.

YEAR FOUNDED:

1858

LEADERSHIP:

Founder: Edward Robinson Squibb

CEO: Giovanni Caforio, MD

CFO: Charles Bancroft

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for Bristol-Myers Squibb job opportunities.

PRODUCTS:

Please click here to see all products.

For more information, visit
www.bms.com and follow us on www.twitter.com/BMSNEWS.

FOLLOW BRISTOL-MYERS SQUIBB:

Tweets by Bristol-Myers Squibb

Key Statistics

Email:
Ownership: Public

Web Site: Bristol-Myers Squibb
Employees:
Symbol: BMY

Industry
Biotechnology
Suppliers
Biopharmaceutical

Segment
Medical Device - Cardiovascular

Collaborations
Gilead
PanVera LLC
Pharmagene Laboratories Limited
Johnson & Johnson
Amersham Biosciences
Lexicon Genetics Incorporated
Athersys Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.
Merck & Co. Diabetes
Affinimark Technologies Inc.
GlaxoSmithKline (North Carolina)
Medarex, Inc.
Gilead (Durham, NC)
Phyton Biotech - Cancer
Gilead (Seattle, WA)

Company News

Bristol-Myers Squibb (BMY) And Nektar Therapeutics (NKTR) Announce Oncology Clinical Collaboration To Evaluate The Combination Of Opdivo(Nivolumab) And NKTR-214 9/27/2016 11:07:34 AM

Nektar Therapeutics (NKTR) To Host Investor & Analyst Conference Call To Discuss New Clinical Collaboration With Bristol-Myers Squibb (BMY) 9/27/2016 10:06:30 AM

Drug Giant Bristol-Myers Squibb (BMY) Ties it Up With Another Bay Area Firm in Cancer Immunotherapy Quest 9/27/2016 5:41:17 AM

Bristol-Myers Squibb (BMY) To Take Part In Leerink Partners Immuno-Oncology Roundtable Conference 9/22/2016 11:13:22 AM

EMA Validates Bristol-Myers Squibb (BMY)’s Type II Variation Application For Opdivo (nivolumab) In Advanced Form Of Bladder Cancer 9/20/2016 11:47:26 AM

Bristol-Myers Squibb (BMY) Awards First "Golden Tickets" For LabCentral To PanTher, Suono Bio 9/20/2016 11:21:21 AM

Bristol-Myers Squibb (BMY) Employees Cycle Coast To Coast To Raise Money And Awareness For Cancer Research 9/7/2016 2:10:50 PM

Bristol-Myers Squibb (BMY) To Present At Bank of America (BAC) And Merrill Lynch Global Health Care Conference 9/7/2016 10:40:03 AM

Bristol-Myers Squibb (BMY) To Announce Results For Third Quarter 2016 On October 27 9/7/2016 10:37:28 AM

European Commission (EC) Approves Bristol-Myers Squibb (BMY)’s ORENCIA (Abatacept) For The Treatment Of Highly Active And Progressive Disease In Adult Patients With Rheumatoid Arthritis Not Previously Treated With Methotrexate 9/6/2016 11:40:36 AM

...

//-->